文献速递免疫规划

恒河猴CMV模型:可溶性gB疫苗与复制缺陷病毒疫苗比较

Comparison of vaccination with rhesus CMV (RhCMV) soluble gB with a RhCMV replication-defective virus deleted for MHC class I immune evasion genes in a RhCMV challenge model.
PubMed 文献 · Vaccine · 2018-12-03

在恒河猴巨细胞病毒(RhCMV)挑战模型中,比较了可溶性gB疫苗与缺失MHC I类免疫逃逸基因的复制缺陷RhCMV疫苗。可溶性gB疫苗诱导的gB抗体和中和抗体滴度更高,且挑战后血液中病毒检出频率更低;而复制缺陷病毒疫苗诱导的RhCMV特异性CD8 T细胞频率更高。所有动物挑战后均感染,尿液和唾液排毒无差异。

要点

  • 可溶性gB疫苗诱导的gB抗体滴度比复制缺陷病毒疫苗高20倍。
  • 可溶性gB疫苗诱导的成纤维细胞中和抗体滴度更高。
  • 复制缺陷病毒疫苗诱导的RhCMV特异性CD8 T细胞频率更高。

核心结论

  • 复制缺陷RhCMV疫苗在诱导细胞免疫上优于可溶性gB疫苗,但诱导的中和抗体和gB抗体滴度更低。
  • 挑战后,可溶性gB疫苗组血液中病毒检出频率低于复制缺陷病毒疫苗组。
  • 两种疫苗均未减少尿液和唾液排毒频率及病毒载量。

研究设计与样本

  • 研究使用恒河猴模型,比较了三种免疫方案:RhCMVRΔgL/178/182-189疫苗肌内接种、可溶性RhCMV gB(铝佐剂/单磷酰脂A)接种和PBS对照。
  • 第二次接种后4周检测免疫反应,随后用RhCMV UCD59株皮下挑战。

主要发现

  • 第二次接种后4周,RhCMVRΔgL/178/182-189疫苗组RhCMV特异性CD8 T细胞频率高于可溶性gB组。
  • 可溶性gB组gB抗体滴度比RhCMVRΔgL/178/182-189组高20倍。
  • 可溶性gB组成纤维细胞中和抗体滴度高于RhCMVRΔgL/178/182-189组。
  • 挑战后所有动物均感染,但可溶性gB组血液中RhCMV检出频率低于RhCMVRΔgL/178/182-189组。
  • 尿液和唾液排毒频率及病毒载量在RhCMVRΔgL/178/182-189组、可溶性gB组和PBS组间无差异。

临床怎么用

  • 在恒河猴模型中,可溶性gB疫苗诱导的体液免疫更强,并降低挑战后血液病毒检出频率。
  • 复制缺陷病毒疫苗诱导细胞免疫更强,但未能降低血液病毒检出频率。
  • 两种疫苗均未减少尿液和唾液排毒,提示需优化疫苗策略以控制黏膜排毒。

局限性

  • 研究为动物模型,结果不能直接外推至人类。
  • 挑战后所有动物均感染,疫苗未能完全预防感染。
  • 未评估疫苗对先天性感染或移植后疾病的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A human cytomegalovirus (HCMV) vaccine to prevent infection and/or reduce disease associated with congenital infection or visceral disease in transplant recipients is a high priority, but has remained elusive. We created a disabled infectious single cycle rhesus CMV (RhCMV) deleted for glycoprotein L (gL) and the MHC class I immune evasion genes Rh178 and Rh182-189, and restored its epithelial cell tropism by inserting the Rh128-131A genes. The resulting virus, RhCMVRΔgL/178/182-189, was used to vaccinate rhesus monkeys intramuscularly and was compared with vaccination of animals with soluble RhCMV glycoprotein B (gB) in alum/monophosphoryl lipid A or with PBS as a control. At 4 weeks after the second vaccination, an increased frequency of RhCMV-specific CD8 T cells was detected in animals vaccinated with the RhCMVRΔgL/178/182-189 vaccine compared to animals vaccinated with soluble gB. In contrast, monkeys vaccinated with soluble gB had 20-fold higher gB antibody titers than animals vaccinated with RhCMVRΔgL/178/182-189. Titers of neutralizing antibody to RhCMV infection of fibroblasts were higher in animals vaccinated with gB compared with RhCMVRΔgL/178/182-189. Following vaccination, monkeys were challenged subcutaneously with RhCMV UCD59, a low passage virus propagated in monkey kidney epithelial cells. All animals became infected after challenge; however, the frequency of RhCMV detection in the blood was reduced in monkeys vaccinated with soluble gB compared with those vaccinated with RhCMVRΔgL/178/182-189. The frequency of challenge virus shedding in the urine and saliva and the RhCMV copy number shed at these sites was not different in animals vaccinated with RhCMVRΔgL/178/182-189 or soluble gB compared with those that received PBS before challenge. Although the RhCMVRΔgL/178/182-189 vaccine was superior in inducing cellular immunity to RhCMV, it induced lower titers of neutralizing antibody and antibody to gB than the soluble gB vaccine; after challenge, animals vaccinated with soluble gB had a lower frequency of virus detection in the blood than those vaccinated with RhCMVRΔgL/178/182-189.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Valencia S, Gill RB, Dowdell KC, et al. Comparison of vaccination with rhesus CMV (RhCMV) soluble gB with a RhCMV replication-defective virus deleted for MHC class I immune evasion genes in a RhCMV challenge model. Vaccine. 2018. PMID: 30522906. doi:10.1016/j.vaccine.2018.08.043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。